CD8A and neoplasm: These results suggested that the anti-CD4 mAb treatment also enhances the translocation of tumor-reactive CD8+ T cells from the dLN to PBL and PBL to the tumor, and that PBL can be used as a substitute for the dLN in the IOCT analysis, at least in part.